• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tempus to Report Second Quarter 2025 Financial Results on August 8

    7/22/25 8:30:00 AM ET
    $TEM
    Computer Software: Programming Data Processing
    Technology
    Get the next $TEM alert in real time by email

    Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 on Friday, August 8, 2025. The company will hold the earnings conference call at 8:00 a.m. ET. The company's quarterly earnings will be released the same day.

    The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following:

    • Conference ID: 7005219
    • Domestic Dial-in Number: (800) 715-9871
    • International Dial-in Number: (646) 307-1963
    • Live Webcast: https://edge.media-server.com/mmc/p/irtvw27b

    About Tempus

    Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250722628587/en/

    Tempus Communications

    Erin Carron

    [email protected]

    Tempus Investor Relations

    Elizabeth Krutoholow

    [email protected]

    Get the next $TEM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TEM

    DatePrice TargetRatingAnalyst
    4/21/2025$60.00Buy
    BTIG Research
    2/25/2025$50.00 → $55.00Overweight → Neutral
    Analyst
    2/12/2025Outperform → Mkt Perform
    William Blair
    2/5/2025$58.00 → $74.00Buy
    TD Cowen
    12/13/2024$60.00Outperform
    Wolfe Research
    12/9/2024$74.00Buy
    Guggenheim
    11/11/2024$45.00 → $65.00Buy → Hold
    Stifel
    10/2/2024$45.00 → $60.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $TEM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BTIG Research initiated coverage on Tempus AI with a new price target

      BTIG Research initiated coverage of Tempus AI with a rating of Buy and set a new price target of $60.00

      4/21/25 8:39:11 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus AI downgraded by Analyst with a new price target

      Analyst downgraded Tempus AI from Overweight to Neutral and set a new price target of $55.00 from $50.00 previously

      2/25/25 7:14:46 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus AI downgraded by William Blair

      William Blair downgraded Tempus AI from Outperform to Mkt Perform

      2/12/25 7:11:34 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Tempus Ai, Inc. exercised 9,218,800 in-the-money shares at a strike of $2.00 and bought $17,745,000 worth of shares (3,500,000 units at $5.07) (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Reporting)

      8/20/24 4:17:55 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Artificial Intelligence Influence in Ophthalmology Industry Projected to Create a Billion Dollar Revenue Opportunity

      MarketNewsUpdates News Commentary NEW YORK, July 22, 2025 /PRNewswire/ -- According to a report from Research And Markets, the AI in Ophthalmology Market was valued at USD 209.23 million in 2024, and is projected to reach USD 1.36 billion by 2030, rising at a CAGR of 36.79%. The rising prevalence of eye diseases, advancements in imaging technology, and expansion of teleophthalmology services are factors contributing to market growth.  The report said: "In addition, growing preference for personalized treatment plans and increasing government initiatives fuel market growth further. The increasing prevalence of eye-related conditions, such as diabetic retinopathy, age-related macular degenerat

      7/22/25 8:45:00 AM ET
      $ALC
      $BLCO
      $JNJ
      $TEM
      Ophthalmic Goods
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Computer Software: Programming Data Processing
    • Tempus to Report Second Quarter 2025 Financial Results on August 8

      Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 on Friday, August 8, 2025. The company will hold the earnings conference call at 8:00 a.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7005219 Domestic Dial-in Number: (800) 715-9871 International Dial-in Numbe

      7/22/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • From Clinics to Cancer Labs, AI Is Unlocking a New $100B+ Era in Medicine

      Equity Insider News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, July 16, 2025 /PRNewswire/ -- Equity Insider News Commentary – Increased usage of AI in healthcare is predicted to not only save lives, but money too. However, the rollout of this industry-changing tech isn't going to happen overnight. The use of AI in healthcare is being pushed by the World Economic Forum (WEF) to provide in its words, a "healthier, more equitable world." A recent study published in Nature introduced a new "AI Affinity Score" designed to measure how comfortable patients are with artificial intelligence in their healthcare journey. The researchers found that factors like education and g

      7/16/25 6:35:00 PM ET
      $MSFT
      $PSNL
      $TEM
      $TVGN
      Computer Software: Prepackaged Software
      Technology
      Medical Specialities
      Health Care

    $TEM
    SEC Filings

    See more
    • Tempus AI Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement

      8-K - Tempus AI, Inc. (0001717115) (Filer)

      7/3/25 5:21:25 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 144 filed by Tempus AI Inc.

      144 - Tempus AI, Inc. (0001717115) (Subject)

      6/17/25 9:45:21 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form 8-K filed by Tempus AI Inc.

      8-K - Tempus AI, Inc. (0001717115) (Filer)

      5/23/25 6:31:57 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Operating Officer Fukushima Ryan sold $300,000 worth of shares (5,000 units at $60.00) (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      7/9/25 4:15:04 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Director Doudna Jennifer A sold $39,075 worth of Class A Comnmon Stock (625 units at $62.52), decreasing direct ownership by 2% to 26,554 units (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      7/3/25 4:15:21 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • CEO and Chairman Lefkofsky Eric P sold $34,876,062 worth of shares (500,000 units at $69.75) (SEC Form 4)

      4 - Tempus AI, Inc. (0001717115) (Issuer)

      6/20/25 4:15:41 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Financials

    Live finance-specific insights

    See more
    • Tempus to Report Second Quarter 2025 Financial Results on August 8

      Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 on Friday, August 8, 2025. The company will hold the earnings conference call at 8:00 a.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7005219 Domestic Dial-in Number: (800) 715-9871 International Dial-in Numbe

      7/22/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus Reports First Quarter 2025 Results

      Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today reported financial results for the quarter ended March 31, 2025. Revenue increased 75.4% year-over-year to $255.7 million in the first quarter of 2025 Quarterly gross profit increased 99.8% year-over-year, reaching $155.2 million with continued gross margin improvement in both Genomics and Data and services Announced multi-year, strategic collaborations with AstraZeneca and Pathos to work together to build the largest multimodal foundation model in oncology, resulting in additional $200.0 million in data licensing and model development fees over the next

      5/6/25 4:01:00 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Tempus to Report First Quarter 2025 Financial Results on May 6

      Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the first quarter of 2025 on Tuesday, May 6, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 4680302 Domestic Dial-in Number: (800) 715-9871 International Dial-in Number: (646) 307

      4/24/25 8:30:00 AM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology

    $TEM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Tempus AI Inc.

      SC 13G - Tempus AI, Inc. (0001717115) (Subject)

      11/12/24 5:00:02 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • SEC Form SC 13G filed by Tempus AI Inc.

      SC 13G - Tempus AI, Inc. (0001717115) (Subject)

      11/12/24 4:30:28 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology
    • Amendment: SEC Form SC 13D/A filed by Tempus AI Inc.

      SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)

      8/20/24 4:27:51 PM ET
      $TEM
      Computer Software: Programming Data Processing
      Technology